<b>Introduction</b>: Despite proven efficacy of anti-TNF agents in inflammatory bowel disease, primary non-response affects up to one-third of patients, while secondary loss of response occurs at 13-21% per patient-year, often requiring dose optimization or switching to alternative advanced therapies. The gene discussed is TNF; the disease is inflammatory bowel disease.